Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 776 entries
Sorted by: Best Match Show Resources per page
Comment: Culture, rigor, and science in educational research

Educational trials

Gutierrez K.
GSID: LzHwYwp0pOcJ
F Erickson, K Gutierrez - Educational Researcher, 2002 - journals.sagepub.com

… for the educational equivalent of thalidomide. That was a medical treatment that was shown scientifically (ie, by means of randomized trials) to … -based social engineering as a means of educational reform appear to us to be unwise,...

Cite
Erickson, F., & Gutierrez, K. (2002). Comment: Culture, rigor, and science in educational research. Educational Researcher, 31(8), 21-24.
Erickson, Frederick, and Kris Gutierrez. "Comment: Culture, rigor, and science in educational research." Educational Researcher 31.8 (2002): 21-24.
Copy Download .nbib Format: MLA
The Prevalence and Management of Systemic Amyloidosis in Western Countries.

Kidney diseases (Basel, Switzerland)

Nienhuis HL, Bijzet J, Hazenberg BP.
PMID: 27536687
Kidney Dis (Basel). 2016 Apr;2(1):10-9. doi: 10.1159/000444206. Epub 2016 Feb 25.

BACKGROUND: Amyloidosis has been a mystery for centuries, but research of the last decennia has clarified many of the secrets of this group of diseases. A protein-based classification of amyloidosis helps to understand problems that were part of the...

Cite
Nienhuis HL, Bijzet J, Hazenberg BP. The Prevalence and Management of Systemic Amyloidosis in Western Countries. Kidney Dis (Basel). 2016;2(1):10-9doi: 10.1159/000444206.
Nienhuis, H. L., Bijzet, J., & Hazenberg, B. P. (2016). The Prevalence and Management of Systemic Amyloidosis in Western Countries. Kidney diseases (Basel, Switzerland), 2(1), 10-9. https://doi.org/10.1159/000444206
Nienhuis, Hans L A, et al. "The Prevalence and Management of Systemic Amyloidosis in Western Countries." Kidney diseases (Basel, Switzerland) vol. 2,1 (2016): 10-9. doi: https://doi.org/10.1159/000444206
Nienhuis HL, Bijzet J, Hazenberg BP. The Prevalence and Management of Systemic Amyloidosis in Western Countries. Kidney Dis (Basel). 2016 Apr;2(1):10-9. doi: 10.1159/000444206. Epub 2016 Feb 25. PMID: 27536687; PMCID: PMC4946260.
Copy Download .nbib Format: NLM
Histiocytic sarcoma; case report of a rare disease in a kidney transplant recipient.

Journal of nephropathology

Ventura Aguiar P, Dias C, Azevedo P, Silva HN, Almeida M, Pedroso S, Martins LS, Dias L, Rodrigues A, Viscaíño R, Cabrita A, Henriques AC.
PMID: 26312238
J Nephropathol. 2015 Jul;4(3):97-100. doi: 10.12860/jnp.2015.18. Epub 2015 Jul 01.

BACKGROUND: Histiocytic sarcoma (HS) is a rare hematologic neoplasm with a few hundred cases having been described to date.CASE PRESENTATION: We report the case of a 56-year-old woman with a history of hepatitis C infection and chronic kidney disease...

Cite
Ventura Aguiar P, Dias C, Azevedo P, et al. Histiocytic sarcoma; case report of a rare disease in a kidney transplant recipient. J Nephropathol. 2015;4(3):97-100doi: 10.12860/jnp.2015.18.
Ventura Aguiar, P., Dias, C., Azevedo, P., Silva, H. N., Almeida, M., Pedroso, S., Martins, L. S., Dias, L., Rodrigues, A., Viscaíño, R., Cabrita, A., & Henriques, A. C. (2015). Histiocytic sarcoma; case report of a rare disease in a kidney transplant recipient. Journal of nephropathology, 4(3), 97-100. https://doi.org/10.12860/jnp.2015.18
Ventura Aguiar, Pedro, et al. "Histiocytic sarcoma; case report of a rare disease in a kidney transplant recipient." Journal of nephropathology vol. 4,3 (2015): 97-100. doi: https://doi.org/10.12860/jnp.2015.18
Ventura Aguiar P, Dias C, Azevedo P, Silva HN, Almeida M, Pedroso S, Martins LS, Dias L, Rodrigues A, Viscaíño R, Cabrita A, Henriques AC. Histiocytic sarcoma; case report of a rare disease in a kidney transplant recipient. J Nephropathol. 2015 Jul;4(3):97-100. doi: 10.12860/jnp.2015.18. Epub 2015 Jul 01. PMID: 26312238; PMCID: PMC4544561.
Copy Download .nbib Format: NLM
Patient with terbinafine-induced subacute cutaneous lupus erythematosus followed by thalidomide-induced orofacial neuropathy; Beta blocker use, hypertension, and the risk of psoriasis; eczematous reaction to intravenous immunoglobulin; nicolau syndrome after intra-articular glucocorticoid injection; troponin leak associated with drug-induced methemoglobinemia.

Hospital pharmacy

Mancano MA.
PMID: 25684795
Hosp Pharm. 2015 Jan;50(1):13-7. doi: 10.1310/hpj5001-013.

The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), discuss methods of prevention, and promote reporting of ADRs to the US Food and Drug Administration's (FDA's) MedWatch program (800-FDA-1088). If you have reported...

Cite
Mancano MA. Patient with terbinafine-induced subacute cutaneous lupus erythematosus followed by thalidomide-induced orofacial neuropathy; Beta blocker use, hypertension, and the risk of psoriasis; eczematous reaction to intravenous immunoglobulin; nicolau syndrome after intra-articular glucocorticoid injection; troponin leak associated with drug-induced methemoglobinemia. Hosp Pharm. 2015;50(1):13-7doi: 10.1310/hpj5001-013.
Mancano, M. A. (2015). Patient with terbinafine-induced subacute cutaneous lupus erythematosus followed by thalidomide-induced orofacial neuropathy; Beta blocker use, hypertension, and the risk of psoriasis; eczematous reaction to intravenous immunoglobulin; nicolau syndrome after intra-articular glucocorticoid injection; troponin leak associated with drug-induced methemoglobinemia. Hospital pharmacy, 50(1), 13-7. https://doi.org/10.1310/hpj5001-013
Mancano, Michael A. "Patient with terbinafine-induced subacute cutaneous lupus erythematosus followed by thalidomide-induced orofacial neuropathy; Beta blocker use, hypertension, and the risk of psoriasis; eczematous reaction to intravenous immunoglobulin; nicolau syndrome after intra-articular glucocorticoid injection; troponin leak associated with drug-induced methemoglobinemia." Hospital pharmacy vol. 50,1 (2015): 13-7. doi: https://doi.org/10.1310/hpj5001-013
Mancano MA. Patient with terbinafine-induced subacute cutaneous lupus erythematosus followed by thalidomide-induced orofacial neuropathy; Beta blocker use, hypertension, and the risk of psoriasis; eczematous reaction to intravenous immunoglobulin; nicolau syndrome after intra-articular glucocorticoid injection; troponin leak associated with drug-induced methemoglobinemia. Hosp Pharm. 2015 Jan;50(1):13-7. doi: 10.1310/hpj5001-013. PMID: 25684795; PMCID: PMC4321423.
Copy Download .nbib Format: NLM
LNO3 AND L3 Are Associated With Antiproliferative And Pro-Apoptotic Action In Hepatoma Cells.

Genetics and molecular biology

Zanelatto LC, Silva PB, Sartori D, Panis C, Lepri S, Fátima Âd, Mantovani MS.
PMID: 27303908
Genet Mol Biol. 2016 Apr-Jun;39(2):270-8. doi: 10.1590/1678-4685-GMB-2015-0184.

The identification of antitumoral substances is the focus of intense biomedical research. Two structural analogues of thalidomide, LNO3 and L3, are two synthetic compounds that might possess such antitumor properties. We evaluated the toxicological effects of these substances, including...

Cite
Zanelatto LC, Silva PB, Sartori D, et al. LNO3 AND L3 Are Associated With Antiproliferative And Pro-Apoptotic Action In Hepatoma Cells. Genet Mol Biol. 2016;39(2):270-8doi: 10.1590/1678-4685-GMB-2015-0184.
Zanelatto, L. C., Silva, P. B., Sartori, D., Panis, C., Lepri, S., Fátima, �. �. d., & Mantovani, M. S. (2016). LNO3 AND L3 Are Associated With Antiproliferative And Pro-Apoptotic Action In Hepatoma Cells. Genetics and molecular biology, 39(2), 270-8. https://doi.org/10.1590/1678-4685-GMB-2015-0184
Zanelatto, Leonardo Campos, et al. "LNO3 AND L3 Are Associated With Antiproliferative And Pro-Apoptotic Action In Hepatoma Cells." Genetics and molecular biology vol. 39,2 (2016): 270-8. doi: https://doi.org/10.1590/1678-4685-GMB-2015-0184
Zanelatto LC, Silva PB, Sartori D, Panis C, Lepri S, Fátima Âd, Mantovani MS. LNO3 AND L3 Are Associated With Antiproliferative And Pro-Apoptotic Action In Hepatoma Cells. Genet Mol Biol. 2016 Apr-Jun;39(2):270-8. doi: 10.1590/1678-4685-GMB-2015-0184. PMID: 27303908; PMCID: PMC4910562.
Copy Download .nbib Format: NLM
Retraction notice to “Thalidomide treatment attenuates chemotherapy-induced gonadal toxicity”.

Fertility and sterility

[No authors listed]
PMID: 25879105
Fertil Steril. 2015 Mar;103(3):863. doi: 10.1016/j.fertnstert.2014.12.108.

No abstract available.

Cite
Retraction notice to “Thalidomide treatment attenuates chemotherapy-induced gonadal toxicity”. Fertil Steril. 2015;103(3):863doi: 10.1016/j.fertnstert.2014.12.108.
(2015). Retraction notice to “Thalidomide treatment attenuates chemotherapy-induced gonadal toxicity”. Fertility and sterility, 103(3), 863. https://doi.org/10.1016/j.fertnstert.2014.12.108
"Retraction notice to “Thalidomide treatment attenuates chemotherapy-induced gonadal toxicity”." Fertility and sterility vol. 103,3 (2015): 863. doi: https://doi.org/10.1016/j.fertnstert.2014.12.108
Retraction notice to “Thalidomide treatment attenuates chemotherapy-induced gonadal toxicity”. Fertil Steril. 2015 Mar;103(3):863. doi: 10.1016/j.fertnstert.2014.12.108. PMID: 25879105.
Copy Download .nbib Format: NLM
Treatment of Light Chain Deposition Disease Using Bortezomib-Based Regimen Followed by Thalidomide-Based Regimen in a Saudi Male.

Case reports in nephrology

Adamu B, Al-Ghamdi M, Ahmad M, Alsaad KO.
PMID: 28083151
Case Rep Nephrol. 2016;2016:7485695. doi: 10.1155/2016/7485695. Epub 2016 Dec 19.

Light chain deposition disease (LCDD) is a rare illness with, as yet, no clear evidence-based guidelines for its treatment. To the best of our knowledge, LCDD has not been previously reported from Saudi Arabia. We present in this report,...

Cite
Adamu B, Al-Ghamdi M, Ahmad M, et al. Treatment of Light Chain Deposition Disease Using Bortezomib-Based Regimen Followed by Thalidomide-Based Regimen in a Saudi Male. Case Rep Nephrol. 2016;2016:7485695doi: 10.1155/2016/7485695.
Adamu, B., Al-Ghamdi, M., Ahmad, M., & Alsaad, K. O. (2016). Treatment of Light Chain Deposition Disease Using Bortezomib-Based Regimen Followed by Thalidomide-Based Regimen in a Saudi Male. Case reports in nephrology, 20167485695. https://doi.org/10.1155/2016/7485695
Adamu, Bappa, et al. "Treatment of Light Chain Deposition Disease Using Bortezomib-Based Regimen Followed by Thalidomide-Based Regimen in a Saudi Male." Case reports in nephrology vol. 2016 (2016): 7485695. doi: https://doi.org/10.1155/2016/7485695
Adamu B, Al-Ghamdi M, Ahmad M, Alsaad KO. Treatment of Light Chain Deposition Disease Using Bortezomib-Based Regimen Followed by Thalidomide-Based Regimen in a Saudi Male. Case Rep Nephrol. 2016;2016:7485695. doi: 10.1155/2016/7485695. Epub 2016 Dec 19. PMID: 28083151; PMCID: PMC5204089.
Copy Download .nbib Format: NLM
Treatment of pyoderma gangrenosum with thalidomide in a myelodysplastic syndrome case.

International medical case reports journal

Malkan UY, Gunes G, Eliacik E, Haznedaroglu IC.
PMID: 27051318
Int Med Case Rep J. 2016 Mar 16;9:61-4. doi: 10.2147/IMCRJ.S101000. eCollection 2016.

Thalidomide may be used as a treatment option for pyoderma gangrenosum (PG) and myelodysplastic syndrome (MDS). Herein, we aimed to report a patient who was treated well with thalidomide and whose diagnosis was PG with MDS. A 61-year-old man...

Cite
Malkan UY, Gunes G, Eliacik E, et al. Treatment of pyoderma gangrenosum with thalidomide in a myelodysplastic syndrome case. Int Med Case Rep J. 2016;9:61-4doi: 10.2147/IMCRJ.S101000.
Malkan, U. Y., Gunes, G., Eliacik, E., & Haznedaroglu, I. C. (2016). Treatment of pyoderma gangrenosum with thalidomide in a myelodysplastic syndrome case. International medical case reports journal, 961-4. https://doi.org/10.2147/IMCRJ.S101000
Malkan, Umit Yavuz, et al. "Treatment of pyoderma gangrenosum with thalidomide in a myelodysplastic syndrome case." International medical case reports journal vol. 9 (2016): 61-4. doi: https://doi.org/10.2147/IMCRJ.S101000
Malkan UY, Gunes G, Eliacik E, Haznedaroglu IC. Treatment of pyoderma gangrenosum with thalidomide in a myelodysplastic syndrome case. Int Med Case Rep J. 2016 Mar 16;9:61-4. doi: 10.2147/IMCRJ.S101000. eCollection 2016. PMID: 27051318; PMCID: PMC4803237.
Copy Download .nbib Format: NLM
An interesting case of Lucio phenomenon triggered by activation of hepatitis C infection.

Indian dermatology online journal

Mareen J, Madhukara J.
PMID: 27730040
Indian Dermatol Online J. 2016 Sep-Oct;7(5):406-409. doi: 10.4103/2229-5178.190498.

Lucio phenomenon (LP) or erythema necroticans is a rare type of reaction pattern found in untreated patients with diffuse non-nodular leprosy. It is important to distinguish this from vasculonecrotic erythema nodosum because thalidomide with high-dose steroids is the mainstay...

Cite
Mareen J, Madhukara J. An interesting case of Lucio phenomenon triggered by activation of hepatitis C infection. Indian Dermatol Online J. 2016;7(5):406-409doi: 10.4103/2229-5178.190498.
Mareen, J., & Madhukara, J. (2016). An interesting case of Lucio phenomenon triggered by activation of hepatitis C infection. Indian dermatology online journal, 7(5), 406-409. https://doi.org/10.4103/2229-5178.190498
Mareen, Jacob, and Madhukara, Jithendriya. "An interesting case of Lucio phenomenon triggered by activation of hepatitis C infection." Indian dermatology online journal vol. 7,5 (2016): 406-409. doi: https://doi.org/10.4103/2229-5178.190498
Mareen J, Madhukara J. An interesting case of Lucio phenomenon triggered by activation of hepatitis C infection. Indian Dermatol Online J. 2016 Sep-Oct;7(5):406-409. doi: 10.4103/2229-5178.190498. PMID: 27730040; PMCID: PMC5038105.
Copy Download .nbib Format: NLM
Leukocytoclastic vasculitis with eosinophilic infiltration associated with thalidomide therapy for multiple myeloma: A case report.

Allergology international : official journal of the Japanese Society of Allergology

Ichiyama S, Funasaka Y, Yamashita H, Tamura H, Inokuchi K, Saeki H.
PMID: 28110897
Allergol Int. 2017 Jul;66(3):497-498. doi: 10.1016/j.alit.2016.12.006. Epub 2017 Jan 16.

No abstract available.

Cite
Ichiyama S, Funasaka Y, Yamashita H, et al. Leukocytoclastic vasculitis with eosinophilic infiltration associated with thalidomide therapy for multiple myeloma: A case report. Allergol Int. 2017;66(3):497-498doi: 10.1016/j.alit.2016.12.006.
Ichiyama, S., Funasaka, Y., Yamashita, H., Tamura, H., Inokuchi, K., & Saeki, H. (2017). Leukocytoclastic vasculitis with eosinophilic infiltration associated with thalidomide therapy for multiple myeloma: A case report. Allergology international : official journal of the Japanese Society of Allergology, 66(3), 497-498. https://doi.org/10.1016/j.alit.2016.12.006
Ichiyama, Susumu, et al. "Leukocytoclastic vasculitis with eosinophilic infiltration associated with thalidomide therapy for multiple myeloma: A case report." Allergology international : official journal of the Japanese Society of Allergology vol. 66,3 (2017): 497-498. doi: https://doi.org/10.1016/j.alit.2016.12.006
Ichiyama S, Funasaka Y, Yamashita H, Tamura H, Inokuchi K, Saeki H. Leukocytoclastic vasculitis with eosinophilic infiltration associated with thalidomide therapy for multiple myeloma: A case report. Allergol Int. 2017 Jul;66(3):497-498. doi: 10.1016/j.alit.2016.12.006. Epub 2017 Jan 16. PMID: 28110897.
Copy Download .nbib Format: NLM
Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options.

Turkish journal of haematology : official journal of Turkish Society of Haematology

Çetin G, Eşkazan AE, Ar MC, Aydın ŞÖ, Ferhanoğlu B, Soysal T, Başlar Z, Aydın Y.
PMID: 25541654
Turk J Haematol. 2014 Dec 05;31(4):374-80. doi: 10.4274/tjh.2013.0004.

OBJECTIVE: This study aimed to investigate the impact of the different therapy regimens used in multiple myeloma (MM) on bone-specific alkaline phosphatase (BALP) levels.MATERIALS AND METHODS: One hundred and thirteen patients with MM were included in the study. Patients...

Cite
Çetin G, Eşkazan AE, Ar MC, et al. Farklı Tedavi Rejimleri Alan Multipl Myelom Hastalarında Kemik Spesifik Alkalen Fosfataz Düzeyleri. Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options. Turk J Haematol. 2014;31(4):374-80doi: 10.4274/tjh.2013.0004.
Çetin, G., Eşkazan, A. E., Ar, M. C., Aydın, �. �. �. �., Ferhanoğlu, B., Soysal, T., Başlar, Z., & Aydın, Y. (2014). Farklı Tedavi Rejimleri Alan Multipl Myelom Hastalarında Kemik Spesifik Alkalen Fosfataz Düzeyleri. Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options. Turkish journal of haematology : official journal of Turkish Society of Haematology, 31(4), 374-80. https://doi.org/10.4274/tjh.2013.0004
Çetin, Güven, et al. "Farklı Tedavi Rejimleri Alan Multipl Myelom Hastalarında Kemik Spesifik Alkalen Fosfataz Düzeyleri." Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options. Turkish journal of haematology : official journal of Turkish Society of Haematology vol. 31,4 (2014): 374-80. doi: https://doi.org/10.4274/tjh.2013.0004
Çetin G, Eşkazan AE, Ar MC, Aydın ŞÖ, Ferhanoğlu B, Soysal T, Başlar Z, Aydın Y. Farklı Tedavi Rejimleri Alan Multipl Myelom Hastalarında Kemik Spesifik Alkalen Fosfataz Düzeyleri. Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options. Turk J Haematol. 2014 Dec 05;31(4):374-80. doi: 10.4274/tjh.2013.0004. PMID: 25541654; PMCID: PMC4454052.
Copy Download .nbib Format: NLM
Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review.

OncoTargets and therapy

He X, Yang K, Chen P, Liu B, Zhang Y, Wang F, Guo Z, Liu X, Lou J, Chen H.
PMID: 25246802
Onco Targets Ther. 2014 Sep 10;7:1593-9. doi: 10.2147/OTT.S67165. eCollection 2014.

Multiple myeloma (MM) is a clonal malignancy characterized by the proliferation of malignant plasma cells in the bone marrow and the production of monoclonal immunoglobulin. Although some newly approved drugs (thalidomide, lenalidomide, and bortezomib) demonstrate significant benefit for MM...

Cite
He X, Yang K, Chen P, et al. Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review. Onco Targets Ther. 2014;7:1593-9doi: 10.2147/OTT.S67165.
He, X., Yang, K., Chen, P., Liu, B., Zhang, Y., Wang, F., Guo, Z., Liu, X., Lou, J., & Chen, H. (2014). Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review. OncoTargets and therapy, 71593-9. https://doi.org/10.2147/OTT.S67165
He, Xuepeng, et al. "Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review." OncoTargets and therapy vol. 7 (2014): 1593-9. doi: https://doi.org/10.2147/OTT.S67165
He X, Yang K, Chen P, Liu B, Zhang Y, Wang F, Guo Z, Liu X, Lou J, Chen H. Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients: a meta-analysis and systematic review. Onco Targets Ther. 2014 Sep 10;7:1593-9. doi: 10.2147/OTT.S67165. eCollection 2014. PMID: 25246802; PMCID: PMC4166211.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 776 entries